CE Disclosures and Faculty Information

• TARGET AUDIENCE
  This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hematologic cancers.
  
  OVERVIEW OF ACTIVITY
  Taken together, it is estimated that approximately 86,520 new non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) cases were identified in the United States in the year 2014, and 23,590 individuals died from these diseases. Of importance, currently more than 60 drug products are labeled for use in the management of hematologic cancers, comprising more than 70 distinct FDA-approved indications. Although this extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses a challenge to the practicing clinician who must maintain up-to-date knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors.

  These proceedings from a CME symposium during the 56^th ASH Annual Meeting use the perspectives of renowned experts in the field of hematologic oncology to frame a relevant discussion of the optimal management of various forms of NHL. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist hematologists, medical oncologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies for NHL.

  
  LEARNING OBJECTIVES

  • Appraise recent data on therapeutic advances and changing practice standards in the non-Hodgkin lymphomas, including chronic lymphocytic leukemia (CLL), and integrate this information, as appropriate, into current clinical care.
  • Develop an algorithm for the risk-stratified induction treatment of follicular lymphoma, diffuse large B-cell lymphoma and mantle-cell lymphoma.
  • Customize the selection of systemic therapy for patients with newly diagnosed and progressive mantle-cell lymphoma, recognizing the addition of recently FDA-endorsed options for these patients.
  • Appreciate the recent FDA approvals of novel targeted agents indicated for the treatment of newly diagnosed and relapsed/refractory CLL, and discern how these treatments can be appropriately integrated into clinical practice.
  • Compare and contrast completed and ongoing clinical trials evaluating novel investigational approaches for B-cell lymphomas and CLL, and use this information to refer appropriate patients for study participation and/or available expanded access programs.
  • Recognize the role of novel agents in the management of peripheral T-cell lymphoma and/or advanced-stage cutaneous T-cell lymphoma, and ensure appropriate supportive care measures to minimize side effects.

  ACCREDITATION STATEMENT
  
  CME credit is no longer available for this issue
  
  CREDIT DESIGNATION STATEMENT
  
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of a video component. The participant should watch the video.
  
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Stephen M Ansell, MD, PhD
  Professor of Medicine
  Division of Hematology
  Mayo Clinic
  Rochester, Minnesota
  
  Research Funding: Bristol-Myers Squibb Company, Celldex Therapeutics.
  
  Brad S Kahl, MD
  Skoronski Chair of Lymphoma Research
  Associate Professor
  University of Wisconsin School of
  Medicine and Public Health
  Associate Director for Clinical Research
  UW Carbone Cancer Center
  Madison, Wisconsin
  
  Advisory Committee: Celgene Corporation, Genentech BioOncology, Roche Laboratories Inc, Takeda Oncology; Contracted Research: Genentech BioOncology, Roche Laboratories Inc.
  
  John P Leonard, MD
  Richard T Silver Distinguished
  Professor of Hematology
  and Medical Oncology
  Associate Dean for Clinical Research
  Weill Cornell Medical College
  New York, New York
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Genentech BioOncology, Spectrum Pharmaceuticals Inc.
  
  Gilles A Salles, MD, PhD
  Professor of Medicine
  Université Claude Bernard
  Head of the Hematology
  Department Hospices Civils
  Lyon, France
  
  Advisory Committee: Celgene Corporation, Gilead Sciences Inc, Janssen Pharmaceuticals Inc, Mundipharma International Limited, Pfizer Inc, Roche Laboratories Inc; Contracted Research: Celgene Corporation, Mundipharma International Limited, Roche Laboratories Inc; Other Remunerated Activities: Amgen Inc, Roche Laboratories Inc.
  
  Julie M Vose, MD, MBA
  Neumann M and Mildred E Harris Professor
  Chief, Division of Hematology/Oncology
  Nebraska Medical Center
  Omaha, Nebraska
  
  Contracted Research: Allos Therapeutics, Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Incyte Corporation, Janssen Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, OncoMed Pharmaceuticals Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Spectrum Pharmaceuticals Inc, US Biotest Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Myriad Genetic Laboratories Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.
  
  RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AbbVie Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Onyx Pharmaceuticals, an Amgen subsidiary and Takeda Oncology.
  
  Hardware/Software Requirements:
  A high-speed Internet connection

  A monitor set to 1280 x 1024 pixels or more

  Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later

  Adobe Flash Player 10.2 plug-in or later

  Adobe Acrobat Reader

  (Optional) Sound card and speakers for audio
  
  Last review date: March 2015
  Expiration date: March 2016